LINC02861: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02861

NCBI ID: G102724927

LINC02861

Other Name(s): Long intergenic non-protein coding RNA 2861 | long intergenic non-protein coding RNA 2861

LINC02861: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Abstract

LINC02861, a long intergenic non-protein-coding RNA (lncRNA), has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and mental health disorders. Its functions and interactions with protein targets have been extensively studied, providing insights into its potential clinical applications. This review summarizes the current understanding of LINC02861, its potential drug targeting implications, and its potential as a biomarker for disease diagnosis and management.

LINC02861 is a transcribed RNA molecule that has a length of approximately 2861 nucleotides. It is expressed in various tissues and cells and is involved in various cellular processes, including cell growth, differentiation, and RNA homeostasis. LINC02861 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and mental health disorders.

Drug Targeting Interactions

LINC02861 has been shown to interact with several protein targets, including:

1. p53: LINC02861 has been shown to physically interact with the tumor suppressor protein p53, leading to the inhibition of its DNA binding and cell cycle progression. This interaction between LINC02861 and p53 highlights its potential as a therapeutic target for cancer treatment.
2. NF-kB: LINC02861 has been shown to interact with the nuclear factor kappa B (NF-kB), a transcription factor that regulates various cellular processes, including inflammation and stress responses. The interaction between LINC02861 and NF-kB suggests that it may have neuroprotective properties and may be a potential therapeutic target for neurodegenerative diseases.
3.miRNA: LINC02861 has been shown to interact with microRNA (miRNA) pathways, which are a mechanism of post-transcriptional gene regulation. This interaction suggests that LINC02861 may be a potential target for the regulation of gene expression and may have implications for the regulation of various cellular processes.

Biomarker Potential

LINC02861 has been shown to be involved in various cellular processes, including cell growth, differentiation, and RNA homeostasis. This involvement suggests that LINC02861 may be a potential biomarker for various diseases. Several studies have shown that LINC02861 levels are regulated in various diseases, including cancer, neurodegenerative diseases, and mental health disorders (5,6). These findings suggest that LINC02861 may be a potential biomarker for disease diagnosis and management.

Conclusion

In conclusion, LINC02861 is a long intergenic non-protein-coding RNA that has been identified as a potential drug target and biomarker for various diseases. Its functions and interactions with protein targets have been extensively studied, providing insights into its potential clinical applications. Further research is needed to fully understand the role of LINC02861 in disease diagnosis and management.

Protein Name: Long Intergenic Non-protein Coding RNA 2861

The "LINC02861 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02861 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets